BioSpace News Archive

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Goldman Sachs 44th Annual Global Healthcare Conference.

BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) announces that it has added Dr. John Paul SanGiovanni, world renowned nutritionist and Harvard-trained scientist, to its Medical and Scientific Advisory board.

SYNAPS Dx a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease, recognizes June 2023 Alzheimer’s & Brain Awareness Month as an opportunity to raise awareness about brain disorders, including AD and other dementias, and the need for more accurate diagnostic tools.

From June 5th to 8th (Pacific Standard Time), the 2023 BIO International Convention (“BIO 2023") will be held in Boston, Massachusetts , USA.

Today, the U.S. Food and Drug Administration is announcing the availability of a draft guidance with updated recommendations for good clinical practices (GCPs) aimed at modernizing the design and conduct of clinical trials, making them more agile without compromising data integrity or participant protections.

Olympus Corporation, a global medical technology company committed to making people’s lives healthier, safer and more fulfilling, announced market availability of its newest electrosurgical generator for use in the treatment of bladder cancer and enlarged prostate.

icometrix , world leader in imaging artificial intelligence (AI) solutions for people with neurological conditions, has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to continue efforts in research towards brain MRI biomarkers for Parkinson’s disease (PD).

Kite, a Gilead Company (Nasdaq: GILD), today announces findings from the largest real-world analysis to date of Tecartus® (brexucabtagene autoleucel) in patients with relapsed or refractory mantle cell lymphoma (R/R MCL).

New data released today at the American Society of Clinical Oncology (ASCO) Annual Meeting highlighted the application of PathomIQ Inc.'s PATHOMIQ_PRAD AI test to assess the risk for metastasis in non-metastatic castration-resistant prostate cancer (nmCRPC).

Emergex Vaccines Holding Limited (‘Emergex’) today announced positive outcomes from its first-in-human clinical trial of DengueTcP (trademark application submitted), a candidate against Dengue virus, the causative agent for Dengue Fever.